Company Overview and News

 
Indraprastha Gas Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-10-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IGL 532514

 
Indraprastha Gas Limited - Change in Director(s)

2018-10-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IGL 532514

 
A $10-billion clean air push set to boost Indian pipe makers

2018-10-15 livemint
Mumbai: Steel pipe makers are set to become beneficiaries of India’s $10 billion push to expand its natural gas network to more of its urban masses and cut pollution. India has just completed its biggest city gas distribution auction that would extend coverage to more than half of its 1.3 billion people across a third of the nation’s area. This project aims to see 10 million homes linked to gas grids by 2020 and bring relief to smog filled cities.
IGL JINDALSAW 513269 500378 MANINDS MAHSEAMLES 532514 500265

 
The US$10-bil clean air drive set to boost Indian pipe makers

2018-10-15 theedgemarkets
(Oct 15): Steel pipe makers are set to become beneficiaries of India’s US$10 billion push to expand its natural gas network to more of its urban masses and cut pollution.
IGL JINDALSAW 513269 500378 MANINDS MAHSEAMLES 532514 500265

 
Indraprastha Gas Limited - Credit Rating

2018-10-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IGL 532514

 
Oil and gas stocks slide up to 12%

2018-10-04 financialexpress
The Oil and gas stocks were among the worst hit on Thursday after the Centre announced a Rs 2.50 per litre cut in petrol and diesel prices. The Centre cut the excise duty by Rs 1.50 a litre, and asked the oil companies to absorb another Rs 1. Shares of state-run OMCs Hindustan Petroleum (HPCL), Bharat Petroleum (BPCL) and Indian Oil (IOC) plummeted by up to 12%, while the BSE Oil and Gas Index closed the day 6.
IOC 500325 BPCL 500547 RELIANCE PQRTY 530965 PETRONET 532514 532522 CSLQY IGL 533106 CASTROLIND OIL BRQPY RIGD GAILY GAILF RLNIY 500870

 
Indraprastha Gas Limited - Appointment

2018-10-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IGL 532514

 
Indraprastha Gas Limited - Shareholders meeting

2018-09-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IGL 532514

 
Indraprastha Gas Limited - Demise

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IGL 532514

 
Indraprastha Gas Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IGL 532514

 
EPCA directs IGL to increase dispensing capacity

2018-09-20 moneycontrol
Taking note of long queues at gas stations leading to traffic woes, the Environment Pollution Control Authority (EPCA) has directed the Indraprastha Gas to increase dispensing capacity of CNG.
IGL 532514

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to NSE:IGL / INDRAPRASTHA GAS LTD. on message board site Silicon Investor.

Biglari Holdings, Inc. Biglari Holdings, Inc. Biglari Holdings, Inc. Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals, Inc. (RIGL)
Internet Gold-(IGLD) Internet Gold-(IGLD) Internet Gold-(IGLD) DIGL... Digital Lightwave.... Making Waves.... DIGL... Digital Lightwave.... Making Waves.... DIGL... Digital Lightwave.... Making Waves....
UNIGLOBE TRAVEL ONLINE (V.UTO.B) UNIGLOBE TRAVEL ONLINE (V.UTO.B) UNIGLOBE TRAVEL ONLINE (V.UTO.B) Uniglobe Travel Uniglobe Travel Uniglobe Travel
Quigley Corp. - QUIG now QGLY ! Whatu0027s next? Quigley Corp. - QUIG now QGLY ! Whatu0027s next? Quigley Corp. - QUIG now QGLY ! Whatu0027s next? Opening a Message board for QGLY- Quigley Co. Opening a Message board for QGLY- Quigley Co. Opening a Message board for QGLY- Quigley Co.